AB076. High expression of FTL protein in prostate cancer and its clinical significance
Printed Abstracts

AB076. High expression of FTL protein in prostate cancer and its clinical significance

Feng-Hong Cao

Department of Urology, the Affiliated Hospital of North China University of Science and Technology, Tangshan 064400, China


Background: To study the differential expression of FTL in prostate cancer and benign prostatic hyperplasia (BPH) and its clinical significance

Methods: Thirty cases of prostate cancer and 30 cases of BPH were selected according to the random number table method, and performed immunohistochemistry experiments; 4 cases of prostate cancer and 4 cases of BPH were collected, and performed protein blotting experiments.

Results: High expression rate of FTL protein in prostate cancer and BPH were 63.3% and 20%, respectively. The difference has statistically significant (P<0.05). The FTL protein was no significant difference in the groups of age, PSA, prostate volume, Gleason score, clinical stage and lymph node metastasis (P>0.05). The expression level of FTL protein has statistically significant in the group of distant metastases (P<0.05). The expression level of FTL protein in prostate cancer and BPH were (1.52±0.27) and (0.41±0.21), respectively, and it has statistically significant (P<0.05).

Conclusions: FTL protein is highly expressed in prostate cancer, and it can be used as a new diagnostic tool for prostate cancer. FTL protein plays an important role in the development of prostate cancer.

Keywords: Prostate cancer; FTL protein; benign prostatic hyperplasia (BPH); diagnostic tool


doi: 10.21037/tau.2017.s076


Cite this abstract as: Cao FH. High expression of FTL protein in prostate cancer and its clinical significance. Transl Androl Urol 2017;6(Suppl 3):AB076. doi: 10.21037/tau.2017.s076